FOXO4-DRI Peptide: Dosage, Protocol, Senolytic Effects, and Anti-Aging Guide
FOXO4-DRI Peptide
FOXO4-DRI (FOXO4 D-Retro-Inverso) is an experimental senolytic peptide designed to disrupt the FOXO4–p53 interaction in senescent cells. Preclinical research has shown selective apoptosis of senescent cells and improvements in several age-related tissue measures in animal models, but FOXO4-DRI has not been validated in human clinical trials.
What Makes FOXO4 Different
FOXO4–p53 Disruption → Senescent-Cell Apoptosis Research → Senolytic Research
FOXO4-DRI is designed to interfere with the interaction between FOXO4 and p53 in senescent cells. In preclinical studies, this can release p53 and promote apoptosis of senescent cells. Whether this produces meaningful anti-aging or longevity benefits in humans has not been established.
FOXO4-DRI is a senolytic peptide, meaning it is discussed for cellular cleanup rather than growth stimulation.
It is not designed for continuous daily use like many standard peptide protocols.
It is usually structured as a short “clearing” cycle followed by a recovery period.
Human data is limited, so conservative cycling and careful monitoring are important.
FOXO4-DRI Research-Use Framework
Short Research-Use Period → Reassessment → Extended Break
Important Evidence Distinction:
FOXO4-DRI does not currently have an established human dosing protocol. The example framework below reflects dosing structures discussed in research-use settings and should not be confused with the mg/kg dosing used in published animal studies.
FOXO4-DRI does not currently have an established human dosing protocol. The example framework below reflects dosing structures discussed in research-use settings and should not be confused with the mg/kg dosing used in published animal studies.
Example Research-Use Setup
Vial
10 mg
Water
3.0 mL bacteriostatic water
Concentration
3.33 mg/mL
Conversion
1 unit ≈ 33.3 mcg
Example Short Research-Use Framework
Not Clinically Established
Example Amount
5 mg
Units
150 units total
Volume
1.50 mL total
Example Frequency
Once per treatment day
Example Duration
3–5 treatment days
Volume Note:
With a 10 mg vial reconstituted with 3.0 mL, a 5 mg amount equals approximately 150 units or 1.50 mL. This exceeds the capacity of a standard 1 mL U-100 insulin syringe. This is one reason vial concentration, dose, and syringe volume should not be treated as interchangeable concepts.
With a 10 mg vial reconstituted with 3.0 mL, a 5 mg amount equals approximately 150 units or 1.50 mL. This exceeds the capacity of a standard 1 mL U-100 insulin syringe. This is one reason vial concentration, dose, and syringe volume should not be treated as interchangeable concepts.
After the Research Period
Next Step
Reassess before considering another period
Required Break
Not established in humans
Continuous Use
Not established by human clinical research
Simple Approach:
FOXO4-DRI is best understood as an experimental senolytic research compound rather than a peptide with an established human protocol. Short intermittent schedules are commonly discussed, but human research has not established an optimal dose, treatment frequency, cycle length, or required time between cycles.
FOXO4-DRI is best understood as an experimental senolytic research compound rather than a peptide with an established human protocol. Short intermittent schedules are commonly discussed, but human research has not established an optimal dose, treatment frequency, cycle length, or required time between cycles.
What the Published Research Actually Shows
FOXO4-DRI has been studied primarily in cellular and animal models.
A standardized human dosing regimen has not been established.
In the landmark 2017 study, FOXO4-DRI was tested in mice using
weight-based dosing rather than fixed human-style microgram or
milligram protocols.
One experiment used 5 mg/kg intravenously every other day on
Days 1, 3, and 5.
Other preclinical FOXO4-DRI studies have used different intermittent
schedules, demonstrating that there is not one universally established
FOXO4-DRI research cycle.
Published research does not establish the previously circulated
250 mcg → 375 mcg → 500 mcg daily progression or a 16-week
continuous human dosing schedule.
Alternative Community / Research-Use Protocol
Important Evidence Distinction:
The gradual protocol below is documented in current peptide research-use and educational dosing sources, but it has not been validated in published human FOXO4-DRI clinical trials. It is included to document a commonly circulated research-use framework, not to present it as an evidence-based human treatment protocol.
The gradual protocol below is documented in current peptide research-use and educational dosing sources, but it has not been validated in published human FOXO4-DRI clinical trials. It is included to document a commonly circulated research-use framework, not to present it as an evidence-based human treatment protocol.
250 mcg → 375 mcg → 500 mcg → Gradual 16-Week Research-Use Framework
Example Setup
Vial
10 mg
Water
3.0 mL bacteriostatic water
Concentration
3.33 mg/mL
Conversion
1 unit ≈ 33.3 mcg
Weeks 1–4
Lower Research-Use Range
Daily Amount
250 mcg
Units
≈ 7.5 units
Volume
≈ 0.075 mL
Frequency
Once daily
Weeks 5–8
Mid Research-Use Range
Daily Amount
375 mcg
Units
≈ 11.25 units
Volume
≈ 0.1125 mL
Frequency
Once daily
Weeks 9–16
Higher Research-Use Range
Daily Amount
500 mcg
Units
≈ 15 units
Volume
≈ 0.15 mL
Frequency
Once daily
Evidence Status
Community / Research-Use
250–500 mcg daily protocols are currently circulated
Human Clinical Validation
None established
Published FOXO4-DRI Research
Primarily cellular and animal studies
Preclinical Dosing
Weight-based mg/kg dosing rather than this fixed microgram schedule
Why both protocols are shown:
FOXO4-DRI research-use communities currently discuss more than one dosing structure. The short 3–5 day framework shown elsewhere on this page and this gradual 16-week framework are both examples of modern research-use approaches. Neither has been established as a standardized human clinical FOXO4-DRI protocol.
FOXO4-DRI research-use communities currently discuss more than one dosing structure. The short 3–5 day framework shown elsewhere on this page and this gradual 16-week framework are both examples of modern research-use approaches. Neither has been established as a standardized human clinical FOXO4-DRI protocol.
Published Research Comparison:
Peer-reviewed FOXO4-DRI studies have used preclinical cellular and animal models. Mouse studies have included intermittent weight-based dosing such as 5 mg/kg, including every-other-day administration in some experiments. Those animal protocols cannot be directly converted into either of the fixed human-style research-use schedules shown on this page.
Peer-reviewed FOXO4-DRI studies have used preclinical cellular and animal models. Mouse studies have included intermittent weight-based dosing such as 5 mg/kg, including every-other-day administration in some experiments. Those animal protocols cannot be directly converted into either of the fixed human-style research-use schedules shown on this page.
How FOXO4 Works
FOXO4 Disruption → p53 Activation → Senescent Cell Apoptosis → Cellular Cleanup
FOXO4-DRI disrupts the FOXO4–p53 interaction in senescent cells.
This may force senescent cells into apoptosis, or programmed cell death.
The goal is to remove dysfunctional cells that contribute to inflammation and aging signals.
Healthier cells may function more efficiently after senescent-cell burden is reduced.
What Are Senescent Cells?
Cells that no longer divide but remain active
Release inflammatory signals known as SASP
Accumulate with age, oxidative stress, and cellular damage
Can contribute to chronic inflammation and aging-related decline
Reconstitution & Dose Conversion (10 mg Vial)
10 mg Vial → Add 3.0 mL → 3.33 mg/mL → Calculate Volume
Reconstitution Setup
Vial Strength
10 mg FOXO4-DRI
Water Added
3.0 mL bacteriostatic water
Concentration
3.33 mg/mL
Per 0.01 mL / 1 Unit
≈ 33.3 mcg
Conversion Reference
1 mg
≈ 30 units / 0.30 mL
2.5 mg
≈ 75 units / 0.75 mL
5 mg
≈ 150 units / 1.50 mL
10 mg
≈ 300 units / 3.00 mL
Volume Note:
These values are mathematical conversions, not established human FOXO4-DRI doses. At this concentration, 5 mg equals approximately 1.50 mL and 10 mg equals 3.00 mL. Both volumes exceed the capacity of a standard 1 mL U-100 insulin syringe.
These values are mathematical conversions, not established human FOXO4-DRI doses. At this concentration, 5 mg equals approximately 1.50 mL and 10 mg equals 3.00 mL. Both volumes exceed the capacity of a standard 1 mL U-100 insulin syringe.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water using a sterile syringe
Add the water slowly down the inside wall of the vial
Gently swirl or roll the vial rather than shaking
Allow the contents to dissolve completely before use
Refrigerate after reconstitution at 2–8°C
Protect from light and label with the reconstitution date
Research Context:
FOXO4-DRI does not have a standardized human dose or reconstitution protocol. The 10 mg / 3.0 mL setup shown here is provided to demonstrate concentration and dose-conversion math and should not be interpreted as a clinically validated preparation or dosing schedule.
FOXO4-DRI does not have a standardized human dose or reconstitution protocol. The 10 mg / 3.0 mL setup shown here is provided to demonstrate concentration and dose-conversion math and should not be interpreted as a clinically validated preparation or dosing schedule.
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (Unmixed Powder)
Short-term storage: keep refrigerated at 2–8°C
Long-term storage: freeze at −20°C / −4°F
Estimated refrigerated shelf life: commonly ~12–24 months when sealed, dry, and protected from light
Estimated frozen shelf life: commonly up to ~2–3 years when stored properly at −20°C / −4°F
Keep the vial sealed until ready to reconstitute
Protect from heat, sunlight, moisture, and repeated temperature swings
Avoid leaving lyophilized peptide at room temperature for extended periods
Do not repeatedly freeze and thaw the same vial
Reconstituted (Mixed)
After mixing: refrigerate at 2–8°C
Use within ~30 days
Do not freeze after mixing
Discard if cloudy, discolored, or if particles appear
Best Practice
Lyophilized FOXO4-DRI is most stable when kept cold, dry, sealed, and protected from light. Once mixed, keep refrigerated and avoid repeated warming cycles.
Lyophilized FOXO4-DRI is most stable when kept cold, dry, sealed, and protected from light. Once mixed, keep refrigerated and avoid repeated warming cycles.
Cycle Length & Time Between Cycles
Short Research-Use Period → Reassess → Extended Break → Repeat if Appropriate
Research-Use Cycle Structure
Example Cycle
3–5 treatment days
Use Style
Short, intermittent research periods
Human Clinical Standard
Not established
Time Between Research Periods
Commonly Discussed Break
4–8 weeks
Required Human Off-Period
Not established
Published human research has not established an optimal FOXO4-DRI cycle frequency.
The 4–8 week interval is a research-use framework rather than a clinically validated recovery period.
Reassessment before another research period avoids presenting FOXO4-DRI as a continuous or maintenance protocol.
Why the distinction matters:
Published FOXO4-DRI research is primarily preclinical and has used intermittent, weight-based dosing in animal models. Human studies have not established that a 3–5 day cycle, a 4–8 week break, or any specific repeating schedule is optimal or required. The timing shown above represents a research-use framework, not a validated human clinical protocol.
Published FOXO4-DRI research is primarily preclinical and has used intermittent, weight-based dosing in animal models. Human studies have not established that a 3–5 day cycle, a 4–8 week break, or any specific repeating schedule is optimal or required. The timing shown above represents a research-use framework, not a validated human clinical protocol.
Monitoring During Use
Injection-site tolerance
Any new or unexpected systemic symptoms
Changes relevant to the defined research goal
Energy, inflammation-related symptoms, or other notable changes during and after the research period
Any prolonged or concerning response after administration
Benefits
Preclinical research has demonstrated selective senolytic activity through disruption of FOXO4–p53 signaling
Animal studies have reported improvements in several age-related tissue and functional measures after senescent-cell targeting
Laboratory studies continue to investigate FOXO4-DRI across cartilage, vascular, and other senescence-related models
FOXO4-DRI remains an experimental compound in senolytic and aging research
Human anti-aging, longevity, and tissue-repair benefits have not been established
Potential Side Effects
Human adverse-effect frequency has not been established
Injection-site irritation may occur with subcutaneous research-use administration
Systemic responses to senolytic activity in humans are not well characterized
Long-term safety and effects of repeated FOXO4-DRI exposure remain unknown
Safety findings from cell or animal studies should not be interpreted as proof of human safety
Best Practices
Treat the displayed protocol as an experimental research-use framework, not a validated clinical regimen
Avoid assuming that repeated or continuous exposure is necessary
Track any unexpected response during and after the defined research period
Account for added complexity before combining FOXO4-DRI with other experimental compounds
Stacking Considerations
FOXO4 Cycle → Recovery Window → Mitochondrial / Repair Support
Stacking Considerations
FOXO4-DRI is sometimes discussed alongside mitochondrial, longevity, or recovery-related research compounds.
Controlled human research has not established specific FOXO4-DRI combination or post-senolytic protocols.
Combining multiple experimental compounds can make individual effects and adverse responses harder to evaluate.
Evidence for individual longevity compounds should not automatically be interpreted as evidence for a combined stack.
Simple rule
Keep the FOXO4 cycle simple. Support compounds are usually better placed after the senolytic phase, when the focus shifts to recovery and cellular repair.
Keep the FOXO4 cycle simple. Support compounds are usually better placed after the senolytic phase, when the focus shifts to recovery and cellular repair.
Important Notes
FOXO4-DRI is an experimental senolytic peptide designed to disrupt FOXO4–p53 signaling in senescent cells.
Published evidence remains preclinical and includes laboratory and animal studies rather than validated human treatment trials.
No standardized human dose, administration frequency, cycle length, maintenance regimen, or required off-period has been established.
The short 3–5 day schedule shown on this page is a research-use framework rather than a validated clinical protocol.
Anti-aging, longevity, inflammation, and tissue-function findings from animal models should not be interpreted as established human outcomes.
Long-term human safety and the consequences of repeated senolytic exposure remain unknown.
Important Disclaimer
FOXO4-DRI is an investigational compound. This content is for educational purposes only and does not constitute medical advice.
Research & References
Primary Research
- Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017. (Original paper introducing FOXO4-DRI.)
- Bourgeois B, Spreitzer E, Platero-Rochart D, et al. The Disordered p53 Transactivation Domain Is the Target of FOXO4 and the Senolytic Compound FOXO4-DRI. Nature Communications. 2025.
- Zhang C, Xie Y, Chen H, et al. FOXO4-DRI Alleviates Age-Related Testosterone Secretion Insufficiency by Targeting Senescent Leydig Cells in Aged Mice. Aging (Albany NY). 2020.
- Hu Z, Li F, Hu C, et al. FOXO4-DRI Regulates Endothelial Cell Senescence via the p53 Signaling Pathway. Frontiers in Bioengineering and Biotechnology. 2026.
Research Note: All published FOXO4-DRI research to date is preclinical — cell culture and aged-mouse studies. There are currently no published human clinical trials establishing safe or effective dosing in humans, so any dosing protocol circulating online is extrapolated from animal studies and community anecdote rather than derived from clinical data.
Comments
Post a Comment